Bladder cancer shows extreme variability in its behavior. Even the superficial forms, when surgically treated, are characterized by a high recurrence rate, and therefore regular and intensive post-treatment monitoring is an important aspect of the management of this tumor. The standard follow-up of patients with a bladder cancer history is based on cystoscopic examination of the internal bladder, which is an invasive procedure causing discomfort to the patient. In this context, the availability of a non-invasive laboratory test which measures circulating markers associated with bladder cancer could facilitate the monitoring of patients and could be of help in understanding the metastatic potential of bladder tumors, especially the superficial forms.
CohenS.M., JohanssonS.L.Epidemiology and etiology of bladder cancer.Urol Clin North Am1992; 19(3): 421–8.
2.
ParkerS.L., TongT., BoldenS., WingoP.A.Cancer statis-tics.CA Cancer J Clin1997; 47: 5–27.
3.
FeldmanA.R., KesslerL., MyersM.H., NaughtonM.D.The prevalence of cancer: estimates based on the Connecticut Tumor Registry.N Engl J Med1986; 315: 1394–7.
4.
MostofiF.K., DavisC.J., SesterhennL.A.Pathology of tumours of the urinary tract. In: SkinnerD.G., LieskovskyG., eds. Diagnosis and management of genitourinary cancer.Philadelphia: WB Saunders, 1988; 83–117.
5.
BaneB.L., RaoJ.Y., HermstreetG.P.Pathology and staging of bladder cancer.Sem Oncol1996; 23(5): 546–70.
6.
TortiF.M., LumB.L.The biology and treatment of superficial bladder cancer.J Clin Oncol1983; 2(5): 505–31.
HeneyN.M., NocksB.N., DalyJ.J.. Ta and T1 bladder cancer: location, recurrence and progression.Br J Urol1982; 54: 152–7.
9.
FitzpatrickJ.M., WestA.B., ButlerM.R., LaneV., O'FlynnJ.D.Superficial bladder tumours (stage pTa, grades 1 and 2): the importance of recurrence pattern following initial resection.J Urol1986; 135: 920–2.
10.
CatalonaW.J., DresnerS.M., HaafE.O.. Diagnosis and management of superficial bladder cancer. In: SkinnerD.G., LieskovskyG., eds. Diagnosis and management of genitourinary cancer.Philadelphia: WB Saunders, 1988; 281–4.
11.
KayeK.W., LangeP.H.Mode of presentation of invasive bladder cancer: Reassessment of the problem.J Urol1982; 128: 31–3.
12.
KakizoeT., TobisuK., TakaiK., TanakaY., KishiK., TeshimaS.Relationship between papillary and nodular transitional cell carcinoma in the human urinary bladder.Cancer Res1988; 48: 2299–303.
13.
YounesM., SussmanJ., TrueL.The usefulness of the level of muscularis mucosae in the staging of invasive transitional cell carcinoma in the urinary bladder.Cancer1990; 66: 543–8.
14.
HudsonM.A., HerrH.W.Carcinoma in situ of the bladder.J Urol1995; 153(3): 564–72.
15.
UtzD.C., FarrowG.M.Carcinoma in situ of the urinary tract.Urol Clin North Am1984; 11: 735–40.
16.
BadalamentR.A., HermansenD.K., KimmelM.. The sensitivity of bladder wash flow cytometry, bladder cytology and voided cytology in the detection of bladder carcinoma.Cancer1987; 60(7): 1423–7.
17.
OomsE.C., AndersonW.A., AlonsC.L., BoonM.E., VeldhuizenR.W.Analysis of the performance of pathology in the grading of bladder tumours.Hum Pathol1983; 14(2): 140–3.
18.
MurphyW.Current status of urinary cytology in the evaluation of bladder neoplasms.Hum Pathol1990; 21: 886–96.
19.
KhannaO.P., WuB.Tissue polypeptide antigen (TPA) as a predictor of genitourinary cancers and their metastases.Urol1987; 30: 106–10.
20.
MaulardC., ToubertM.E., ChretienY., DelanianS., DufourB., HoussetM.Serum tissue polypeptide antigen (s-TPA) in bladder cancer as a tumour marker.Cancer1994; 73: 394–8.
21.
StieberP., DienermannH., HasholznerU.. Comparison of CYFRA 21-1, TPA and TPS in lung cancer, urinary bladder cancer and benign diseases.Int J Biol Markers1994; 9(2): 82–8.
22.
Van PoppelH., BillenJ., GoethuysH.. Serum tissue polypeptide antigen (TPA) as tumour marker for bladder cancer.Anticancer Res1996; 16: 2205–8.
23.
FilellaX., MenendezV., MolinaR., AlcoverJ., CarreteroP., BallestaA.M.TPA prognostic value in superficial bladder cancer.Anticancer Res1996; 16: 2173–6.
24.
PectasidesD., BafaloucosD., AntoniouF.. TPA, TATI, CEA, AFP, ß-hCG, PSA, SCC and CA19.9 for monitoring transitional cell carcinoma of the bladder.Am J Clin Oncol1996; 19(3): 271–7.
25.
VogelJ., OehrP., MaiseyR., AdolphsH.D.Comparison between tissue antigen analysis and plasma determination for TPA and CEA in transitional cell carcinomas and in tumour-free urothelium of the urinary bladder.Cancer Det Prev1988; 11: 389–96.
26.
CasettaG., PianaP., CavalliniA., VotteroM., TizzaniA.Urinary levels of tumour associated antigens (CA19.9, TPA and CEA) in patients with neoplastic and non neoplastic urothelial abnormalities.Br J Urol1993; 72: 60–4.
27.
TizzaniA., CasettaG., CicigoiA.. Tumour markers (CEA, TPA, and CA19.9) in urine of bladder cancer patients.Int J Biol Markers1987; 2(2): 121–4.
28.
HalimA.B., El-AhmadyO., HamzaS., Aboul-ElaM., OehrP.Simultaneous determination of urinary CEA, ferritin and TPA in Egyptian bladder cancer patients.Int J Biol Markers1992; 7(4): 234–9.
29.
El-AhmadyO., Abdel-BassetH., AymanGE-D. The clinical value of CYFRA 21-1 of bladder cancer patients: Egyptian experience.Anticancer Res1997 (Abstract n. 66); 17: 4203.
30.
AbelP., CornellC., BuamahP.. Assessment of serum CA19.9 as a tumor marker in patients with carcinoma of the bladder and prostate.Br J Urol1987; 59: 427–9.
31.
MansourO.A., ShoumanS.A., KhafagyM.. Urinary CA19.9 as marker for bladder cancer.Lancet1995; 346: 512.
32.
DexeusF., LogothetisC., HossanE., SamuelsM.L.Carcinoembryonic antigen and beta-human chorionic gonadotropin as serum markers for advanced urothelial malignancies.J Urol1986; 136: 403–7.
33.
FraserR.A., RavryM.J., SeguraJ.W., GoV.L.W.Clinical evaluation of urinary and serum carcinoembryonic antigen in bladder cancer.J Urol1975; 114: 226–9.
34.
ZimmermanR., WahrenB., EdsmysF.Assessment of serial CEA determinations in urine of patients with bladder carcinoma.Cancer1980; 46: 1802–9.
35.
KeeseeS., BriggmanJ.B., ThillG., WuY.I.Utilization of nuclear matrix proteins for cancer diagnosis. In: SteinG., ed. Critical review in eukaryotic gene expression.1996; 6: 189–214.
36.
ZeitlinS., ParentA., SilversteinS., EfstratiadisA.Pre-mRNA splicing and the nuclear matrix.Mol Cell Biol1987; 7(1): 111–20.
37.
NakayasuH., BerezneyR.Mapping replicational sites in the eukaryotic cell nucleus.J Cell Biol1989; 108: 1–11.
38.
YangC.H., LambieE.J., SnyderM.NuMA: An unusually long coiled-coil related protein in the mammalian nucleus.J Cell Biol1992; 116(6): 1303–17.
39.
ComptonD.A., ClevelandD.W.NuMA is required for the proper completion of mitosis.J Cell Biol1993; 120: 947–57.
40.
CarpinitoG.A., StadlerW.M., BriggmanS.J.. Urinary nuclear matrix protein as a marker for transitional cell carcinoma of the urinary tract.J Urol1996; 156: 1280–5.
41.
SolowayM.S., BriggmanJ.V., CarpinitoG.A.. Use of a new tumor marker, urinary NMP22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment.J Urol1996; 156: 363–7.
42.
LüdeckeG., EdlerM., MillerJ., FischerC., KrausS., WeidnerW.Nuclear matrix protein (NMP22) - a powerful urine marker in tumor screening and follow-up in bladder cancer.Anticancer Res1997 (Abstract n. 71); 17: 4204.
43.
BrunelleS., KindersB., MurchisonH., PfalzgrafR., RootR.Rapid detection of bladder tumour antigen in urine with the Bard® BTA stat™ assay.International Congress of Clinical Chemistry, Wembley (UK), July 1996 (Abstract N. 50346).
44.
SarosdyM.F., Hudson M'LissA., EllisW.J.. Detection of recurrent bladder cancer using a new one-step test for bladder tumor antigen.J Urol1997 (Abstract N. 1318); 157(4): 337.
45.
UK and EIRE Study Group. The BTA stat™ test in the diagnosis of bladder cancer.Br J Urol (Poster N.CP5)1997; 79(Suppl 4).
46.
SarosdyM.F., deVere WhiteR.W., SolowayM.S.. Results of a multicenter trial using the BTA test to monitor for and diagnose recurrent bladder cancer.J Urol1995; 154: 379–84.
47.
D'HallewinM.A., BaertL.Initial evaluation of the bladder tumor antigen test in superficial bladder cancer.J Urol1996; 155: 475–6.
48.
Leyh. Results of a European multicenter trial comparing the Bard BTA test to urine cytology in patients suspected of having bladder cancer.J Urol1996; 155: 492A.
49.
EnfieldD., IshakL., WileyM.. The Bard BTA TRAK™ quantitative enzyme immunoassay for the measurement of bladder tumour antigen in urine.Clin Chem1997 (Abstract n. 535); 43 (Suppl. 6): S222.
50.
KindersR.J., JonesJ., RootR.. Human bladder tumour antigen is a member of the RCA (Regulators of Complement Activation) gene family.J Urol1997 (Abstract n. 110); 157 (Suppl. 4): 28.
51.
KindersR.J., RootR., JonesJ., BruceC.L., HassG.M.Complement factor H-related proteins are expressed in bladder cancer.Proc Eighty-eighth Ann Meet Ass Cancer Res1997, San Diego (Abstract n. 189); 38: 29.
52.
AustynJ.M., WoodK.J.Principles of cellular and molecular immunology.Oxford University Press1993; 522–54.
53.
EllisW.J., BlumensteinB.A., IshakL.M.. Clinical evaluation of the BTA TRAK assay and comparison to voided urine cytology and the Bard BTA test in patients with recurrent bladder tumors.J Urol1997; 50: 882–7.
54.
EllisW.J.Clinical evaluation of the Bard® BTA TRAK™ test: comparison with voided urinary cytology in patients with recurrent bladder tumors.Clin Chem1997 (Abstract N. 534); 43 (Suppl. 6): S222.
55.
RasmussenH.H., OrntoftT.F., WolfH., CelisJ.E.Towards a comprehensive database of proteins from the urine of patients with bladder cancer.J Urol1996; 155: 2113–9.
56.
ZeinT.A., MiladM.F.Urine cytology in bladder tumors.Int Surg1991; 76(1): 52–4.
